Tuesday April 28th 2026 - Day 1 - CT (China Time, GMT+08:00)
- Which cell and gene therapy modalities, disease areas, and technologies are top priorities for big pharma investment?
- What are big pharma looking to license in the next 9-12 months?
- What are the key breakthroughs shaping pharma’s next moves in CGT?
- What are the priorities for the Chinese community and how can Chinese biotech’s align with big pharma’s R&D needs?
- Tony (Bizuo) Liu - Chairman and CEO, AbelZeta Pharma, Inc.
- Snapshot into the investment landscape for cell and gene therapy products and enabling technologies for 2026/ 2027 and beyond
- Technology evaluation and product development areas – What are investors interested in investing in, for China and globally?
- Positioning for success in a competitive funding environment: What do investors need to see?
- Jieyu Zou - Partner, LAV
- Matthieu Coutet - Partner, Sofinnova Partners
- William Sun - Director, China Head of Healthcare, Citi Commercial Bank, Citi
- Act Early, Transform Lives: The transformative, long-lasting impact of autologous HSC gene therapy and the importance of pre-symptomatic intervention enabled by Newborn Screening.
- From Rare to Prevalent: The evolution from single-gene rare diseases toward scalable therapeutic platforms with potential in higher-prevalence indications.
- Scaling the Vein-to-Vein Journey: The operational roadmap required to enable high-volume delivery and COGs reduction, including DP automation, vector scale-up, and expansion of specialized treatment centres.
- Navigating Financial and Regulatory Complexity: How the biotech industry can progress despite funding constraints, market volatility, regulatory complexity and global supply-chain challenges.
- Nicoletta Loggia - Chief Technical Officer, Orchard Therapeutics
Details of the clinical development and regulatory communication for IM19, a novel CD19 CAR-T product under NMPA review. We will highlight the molecule design guided by clinical unmet needs and its demonstrated advantages, including a >70% ORR with low rates of severe CRS/ICANS.
- Ting He - Founder and CEO, Imunopharm Technology Co., Ltd.
- Ivan Lin - Head of Manufacturing and Head of MSAT & ATS, JW Therapeutics
Spotlight Presentation – Calling all Technology Thought Leaders!
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: RShah@informaconnectls.com
- Wenshi Wang - SVP Tech & Ops, FosunKairos
Spotlight Presentation – Calling all Technology Thought Leaders!
Whether you're increasing your company profile, launching a new product or focusing on new business development opportunities, collaborate with us to identify custom solutions to help you reach your goals.
Contact us today to learn more: RShah@informaconnectls.com
In recent years, while innovative therapies using cells have attracted attention, high drug prices have become a dilemma. One of the keys to the advancement of cell therapy products is manufacturing automation through robotics and AI. In this presentation, I will explore global trends in research and development, introduce specific examples of strengthening manufacturing processes, reducing costs, and data driven process optimization, and demonstrate the possibilities for innovation.
- Hideto Yamaguchi - President & CEO, Cellafa Bioscience Inc.
- Wonjong Si (pending final confirmation) - Director, Cell Therapy Platform Process, Bayer